Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: Correlation with galactomannan antigenemia

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 3, 2001, Pages 857-869

  Petraitiene, R ^a   Petraitis, V ^a   Groll, A H ^a   Sein, T ^a   Piscitelli, S ^a   Candelario, M ^a   Field Ridley, A ^a   Avila, N ^a   Bacher, J ^a   Walsh, T J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMPHOTERICIN B DEOXYCHOLATE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; GALACTOMANNAN; ITRACONAZOLE; POSACONAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; ASPERGILLUS FUMIGATUS; COLONY FORMING UNIT; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; FEMALE; LUNG ASPERGILLOSIS; LUNG INFARCTION; LUNG WEIGHT; MINIMUM INHIBITORY CONCENTRATION; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; RABBIT;

ANIMALS; ANTIBIOTIC PROPHYLAXIS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; DISEASE MODELS, ANIMAL; FEMALE; ITRACONAZOLE; LUNG DISEASES, FUNGAL; MANNANS; NEUTROPENIA; RABBITS; TREATMENT OUTCOME; TRIAZOLES;

EID: 0035118426     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.3.857-869.2001     Document Type: Article

References (51)

1. SCH 56592. Amphotericin B, or itraconazole therapy of experimental murine cerebral phaeohyphomycosis due to Ramichloridium obovouleum ("Ramichloridium mackenziel")
2. Dose-dependent antifungal activity and nephrotoxicity of amphotericin B colloidal dispersion in experimental pulmonary aspergillosis
3. Opportunistic mycoses in the immunocompromised host: Experience at a cancer center and review
4. In vitro activities of the new antifungal triazole SCH 56592 against common and emerging yeast pathogens
5. Itraconazole for experimental pulmonary aspergillosis: Comparison with amphotericin B, interaction with cyclosporin A, and correlation between therapeutic response and itraconazole concentration in plasma
6. Cytochromes P450 in fungi
7. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery
8. Comparison of a new triazole antifungal agent. Schering 56592, with itraconazole and amphotericin B for treatment of histoplasmosis in immunocompetent mice
9. Epidemiology of invasive fungal infections in bone marrow transplantation
10. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK.0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts
11. Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi
12. Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits: The potential role of bronchoalveolar Dmannitol and serum galactomannan as markers of infection
13. In vitro studies of activities of the antifungal triazoles SCH 56592 and itraconazole against Candida albicans. Cryptococcus neoformans, and other pathogenic yeasts
14. Amphotericin B: 30 Years of clinical experience
15. SCH 56592 treatment of murine invasive aspergillosis
16. Clinical pharmacology of systemic antifungal agents: A comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development
17. Five-year-survey of invasive aspergillosis in a pediatric cancer centre. Epidemiology, management and long-term survival
18. Rapid and sensitive high performance liquid chromatographic method for the determination of itraconazole and its hydroxy-metabolite in human serum
19. In-vitro and in-vivo activities of SCH56592 against Cryptococcus neoformans
20. Radiologic-pathologic correlation of the CT halo sign in invasive pulmonary aspergillosis
21. Highperformance liquid chromatographic analysis of the anti-fungal agent SCH 56592 in dog serum
22. Efficacy of SCH56592 in a rabbit model of invasive aspergillosis
23. The search for the new triazole antifungal agents
24. Invasive pulmonary aspergillosis in acute leukemia: Characteristic findings on CT, the CT halo sign, and the role of CT in early diagnosis
25. Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp
26. Treatment of murine fusariosis with SCH 56592
27. Activity of the triazole SCH 56592 against disseminated murine coccidioidomycosis
28. Autopsy-controlled prospective evaluation of serial screening for circulating galactomannan by a sandwich enzyme-linked immunosorbent assay for hematological patients at risk for invasive aspergillosis
29. In vitro activity of a new triazole antifungal agent, Sch 56592, against clinical isolates of filamentous fungi
30. Pharmacokinetics of SCH 56592, a new azole broad-spectrum antifungal agent, in mice, rats, rabbits, dogs, and cynomolgus monkeys
31. In vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus spp
32. Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus
33. Nosocomial pneumonia in patients having bone marrow transplant. Attributable mortality and risk factors
34. Role of newer azoles in surgical patients
35. In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans
36. In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-20747, Sch 56592, and voriconazole
37. Activity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae
38. Prospective sandwich enzymelinked immunosorbent assay for serum galactomannan: Early predictive value and clinical use in invasive aspergillosis
39. Amphotericin B: Still the 'gold standard' for antifungal therapy
40. Current and emerging azole antifungal agents
41. A new sensitive sandwich enzyme-linked immunosorbent assay to detect galactofuran in patients with invasive aspergillosis
42. In vitro activity and in vivo activities of SCH 56592 against Blastomyces dermatitidis
43. Sandwich enzyme-linked immunosorbent assay compared with pastorex latex agglutination test for diagnosing invasive aspergittosis in immunocompromised patients
44. Tissue homogenization with sterile reinforced polyethylene bags for quantitative culture of Candida albicans
45. Recent progress and current problems in treatment of invasive fungal infections in neutropenic patients
46. Therapeutic monitoring of experimental invasive pulmonary aspergillosis by ultrafast computerized tomography, a novel, noninvasive method for measuring responses to antifungal therapy
47. Chronic silastic central venous catheterization for induction, maintenance, and support of persistent granulocytopenia in rabbits
48. Application of Akaike's information criterion in the evaluation of linear pharmacokinetic equations